Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 1743-1747

  Engblom, Pirjo ^a   Rantanen, Virpi ^a   Kulmala, Jarmo ^a   Grènman, Seija ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemosensitivity in vitro; Cisplatin; Ovarian carcinoma; Paclitaxel

Indexed keywords

CISPLATIN; PACLITAXEL;

ARTICLE; CELL LINE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG ACTIVITY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE; CELL SURVIVAL; CISPLATIN; CYSTADENOCARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0029776807     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hoskins WJ: Management of Advanced Epithelial Ovarian Cancer. In- Principles and practice of Gynecologic Oncology. Perez CA, Young RC,eds. Philadelphia, Penn: Lippincott J B, pp 753-63,1992.
2. Gelmon K, Nabholtz JM, Bontenbal M, et al: Randomized trial of two doses of paclitaxel in metastatic breast cancer after failure of standard therapy. Ann Oncol 5: suppl. 5, 198, 1994.
3. Ohnoshi T, Takigawa N, Ueoka H, et al: Antitumor activity of taxol against human lung cancer cell lines. Haigan 33: 348-349, 1993.
4. Baquley et al: Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumor cells cultured from patients with ovarian cancer. Eur Jour Cancer 31 A(2): 230-237,1995.
5. Untch M, Untch A, Sevin B-U, et al: Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anti-Cancer Drugs 5: 24-30, 1994.
6. McGuire WP, Rowinsky EK, Rosenhein NB, et al: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann Intern Med 111: 273, 1989.
7. Ozols RF: USA update on paclitaxel in ovarian cancer. Ann Med 27: 127-130, 1995.
8. Cahan MA, Walter KA, Colvin OM, Brem H' Cytotoxicity of Taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33: 441-444, 1994.
9. Figg WD, Thibault A, McCall NA, et al: The in vitro activity of taxol on three hormone refractory prostate cancer (HRPC) cell lines, PC3,DU145, and PC3M. Proc Am Assoc Cancer Res 35: 431, 1994.
10. Ettinger DS, Finkelstein DM, Sarma R, Johnson DH: Phase II study of Taxol in patients with extensive stage small cell lung cancer (SCLC). An Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 12: 329, 1993.
11. Ajani JA, Ilson D, Daugherty K, et al: Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: 1086-1091, 1994.
12. Forastiere AA: Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 20: 56-60, 1993.
13. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. I Natl Cancer Inst 89: 1797-1805, 1991.
14. Rantanen V, Grénman S, Kulmala J, Grénman R: Endometrial cancer cell lines are sensitive to paclitaxel. Anticancer Res, in press, 1996.
15. Jaakkola M, Rantanen V, Grénman S, Kulmala J, Grénman RQ Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro. Submitted.
16. Rantanen V, Grénman S, Kulmala J, Grénman R: Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. Br J Cancer 69: 482-486, 1994.
17. Grénman R, Burk D, Virolainen E, Buick RN, Church J, Schwartz DR, Carey TE: Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-136, 1989.
18. Fogh J, Wright WC, Loveless JDb Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58: 209-214, 1977.
19. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR: Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527-534, 1989.
20. Kelland LR, Abel G: Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444-450, 1992.
21. Silvestrini R, Zaffaroni N, Orlandi L, Oriana S: In vitro cytotoxic activity of Taxol and taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells 11: 528-535, 1993.
22. Weisenthal LM, Dill PL, Kurnick NB, et al: Comparison of dye exlusion asssau with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 43: 258-264, 1983.
23. Khoo SK, Hurst T, Webb MJ, Mackay EV: Short-term in vitro chemosensitivity testing of tumours of the ovary, cervix and uterus. Aust N Z J Obstet Gynaecol 26: 288-294, 1986.
24. Garewal HS, Ahmann FR, Schifman RB, et al: ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. J Natl Cancer Inst 77: 1039-1045, 1986.
25. Rotman B, Teplitz C, Dickinson K, Cozzolino JP: Individual human tumours in short-term micro-organ cultures: chemosensitivity testing by fluorescent cytoprinting. In Vitro Cell Dev Biol 24: 1137-1146, 1988.
26. Von Hoff DD, Kronmal R, Salmon SE, et al: A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 67: 20-27, 1991.
27. Welander CE: Ovarian cancer: The way ahead (Sharp and Southern, Eds.) Royal College Ob/Gyn, London 1987.
28. Shinohova K, Nakano H: Interphase death and reproductive death in x-irradiated MOLT-4 cells. Radiat Res 135: 197-205, 1993.
29. Wennerberg J, Alm P, Bjorklund A, Killander D, Langstrom E, Tropé C: Cell cycle perturbations in heterotransplanted squamous cell carcinoma of head and neck after mitomycin C and cisplatin treatment. Int J Cancer 33: 213-222, 1984.
30. Scerman SE, Lippard SJ: Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 87: 1153-1181, 1987.
31. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assem bly in vitro by Taxol. Nature 277: 665-667, 1979.
32. Manfredi JJ, Parness J, Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94: 688-696, 1982.
33. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
34. Cook JA, Fisher J, Teaque D, et al: Sequence dependent of paclitaxel combined with cisplatin or alkylators in human cancer cells. Proc Am Assoc Cancer Res 35: 332, 1994.
35. Liebman J, Cook JA, Lipscultz C, et al: The influenze of cremphor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33: 331-339, 1994.
36. Swenerton, Eisenhauer E, Bokkel-Huinink W, et al: Taxol in relapsed ovarian cancer: High vs low dose and short vs long infusion. An European Canadian study coordinated by the NCI Canada Trials Group. Proc Am Soc Clin Oncol 12: 256, 1993.
37. Georgiadis MS, Russel E, Johnson BE: Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotoxicity. Proc Am Assoc Cancer Res 35: 341, 1994.
38. Thigpen T, Blessing J, Ball H, Hummel S, Barrett R: Phase II trial of Taxol as second-line therapy for ovarian carcinoma: a Cynecologic Oncology Group study. Proc Am Soc Clin Oncol 9: 156, 1990.
39. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study of taxol in patients with advanced avarian cancer. Ann Assoc Cancer res. 31: 187, 1990.
40. Kohn EC, Sarosy G, Bicher A, et al: Dose-Intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18-24, 1994.
41. Trope C, Bertelsen K, Simonsen E, et al: A phase II multicenter non-randomized study of paclitaxel (Taxol) in patients with previously untreated FIGO stage III suboptimally resected ovarian cancer. Int J Gyn Cancer 4: 7-12, 1994.
42. Untch M, Sevin B-U, Perras JP, et al: Evaluation of paclitaxel (Taxol), cisplatin and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP-cell viability assay. Gynecol Oncol 53: 44-49, 1994.
43. Woodhouse JR, Ferry DR: The genetic basis of resistance to cancer chemotherapy. Ann Med 27: 157-167, 1995.
44. Cabrai FR, Brady RC, Schibler MJ: A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann Ny Acad Sci 466: 745-56, 1986.